Wechselwirkungen von Mercaptopurin

Mercaptopurin (Purixan), ein Antimetabolit, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 109 dokumentierte Wechselwirkungen: 13 schwerwiegende, 81 mittelschwere, 14 geringfügige und 1, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (13)

  • AdalimumabImmunsuppressivumSchwerwiegend

    Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. (Fachinformation zu Adalimumab, Boxed Warning (umrahmter Warnhinweis))

  • CaptoprilACE-HemmerSchwerwiegend

    About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (Fachinformation zu Captopril, Warnhinweise)

  • CiclosporinImmunsuppressivumSchwerwiegend

    In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. (Fachinformation zu Ciclosporin, Boxed Warning (umrahmter Warnhinweis))

  • CladribinAntimetabolitSchwerwiegend

    Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (Fachinformation zu Cladribin, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelSchwerwiegend

    Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy. (Fachinformation zu Darunavir, Arzneimittelwechselwirkungen)

  • FebuxostatXanthinoxidasehemmerSchwerwiegend

    ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (Fachinformation zu Febuxostat, Gegenanzeigen)

  • FludrocortisonKortikosteroidSchwerwiegend

    Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (Fachinformation zu Fludrocortison, Warnhinweise)

  • FlunisolidKortikosteroidSchwerwiegend

    Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (Fachinformation zu Flunisolid, Vorsichtsmaßnahmen)

  • InfliximabImmunsuppressivumSchwerwiegend

    Almost all had received azathioprine or 6- mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. (Fachinformation zu Infliximab, Boxed Warning (umrahmter Warnhinweis))

  • ItraconazolAzol-AntimykotikumSchwerwiegend

    Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (Fachinformation zu Itraconazol, Arzneimittelwechselwirkungen)

  • MesalazinSalicylatSchwerwiegend

    If concomitant use of APRISO and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts. (Fachinformation zu Mesalazin, Arzneimittelwechselwirkungen)

  • Nirmatrelvir und RitonavirVirostatikumSchwerwiegend

    …methylergonovine • HMG-CoA reductase inhibitors: lovastatin, simvastatin (these drugs can be temporarily discontinued to allow PAXLOVID use [see Table 2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists:… (Fachinformation zu Nirmatrelvir und Ritonavir, Gegenanzeigen)

  • TacrolimusImmunsuppressivumSchwerwiegend

    …IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. (Fachinformation zu Tacrolimus, Boxed Warning (umrahmter Warnhinweis))

Mittelschwere Wechselwirkungen (81)

  • AbataceptImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • AbrocitinibJAK-InhibitorMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • AlemtuzumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • AllopurinolXanthinoxidasehemmerMittelschwer

    Reduce the dose of mercaptopurine tablets when coadministered with allopurinol [see Dosage and Administration (2.4)] . (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • AminophyllinMethylxanthinMittelschwer

    Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • AmlodipinDihydropyridin-CalciumkanalblockerMittelschwer

    Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin, Arzneimittelwechselwirkungen)

  • Amlodipin und AtorvastatinDihydropyridin-CalciumkanalblockerMittelschwer

    Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin und Atorvastatin, Arzneimittelwechselwirkungen)

  • Amlodipin und OlmesartanDihydropyridin-CalciumkanalblockerMittelschwer

    Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Amlodipin und Olmesartan, Arzneimittelwechselwirkungen)

  • Amlodipin und ValsartanDihydropyridin-CalciumkanalblockerMittelschwer

    Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (Fachinformation zu Amlodipin und Valsartan, Arzneimittelwechselwirkungen)

  • ApixabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • ArgatrobanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Atazanavirantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: cyclosporine, sirolimus, tacrolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for these immunosuppressants when coadministered with REYATAZ. (Fachinformation zu Atazanavir, Arzneimittelwechselwirkungen)

  • AzathioprinImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • BalsalazidSalicylatMittelschwer

    Azathioprine or 6-Mercaptopurine: Increased risk of blood disorders; monitor complete blood cell counts and platelet counts. (Fachinformation zu Balsalazid, Arzneimittelwechselwirkungen)

  • BaricitinibJAK-InhibitorMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • BendamustinMittelschwer

    Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (Fachinformation zu Bendamustin, Warnhinweise und Vorsichtsmaßnahmen)

  • BivalirudinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • CyclophosphamidImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • DabigatranAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelMittelschwer

    Therapeutic drug monitoring is recommended with concomitant use Immunosuppressant /neoplastic: everolimus ↑ immunosuppressants Co-administration of everolimus and PREZCOBIX or PREZCOBIX PED is not recommended. irinotecan Discontinue PREZCOBIX or PREZCOBIX PED at least 1 week prior to starting irinotecan therapy. (Fachinformation zu Darunavir und Cobicistat, Arzneimittelwechselwirkungen)

  • DenosumabMittelschwer

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (Fachinformation zu Denosumab, Warnhinweise und Vorsichtsmaßnahmen)

  • DimethylfumaratImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • DoxorubicinMittelschwer

    Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. (Fachinformation zu Doxorubicin, Arzneimittelwechselwirkungen)

  • EdoxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Efavirenzantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: Cyclosporine, tacrolimus, sirolimus and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (Fachinformation zu Efavirenz, Arzneimittelwechselwirkungen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A ↓ immunosuppressant Dose adjustments of the immunosuppressant may be required. (Fachinformation zu Efavirenz, Lamivudin und Tenofovir, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Immuno-suppressants: e.g., cyclosporine (CsA) sirolimus tacrolimus ↑ immuno-suppressants ↑ elvitegravir (with CsA) ↑ cobicistat (with CsA) Therapeutic monitoring of the immunosuppressive agents is recommended upon coadministration with GENVOYA. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

  • EnoxaparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Ergotamin und KoffeinMutterkornalkaloidMittelschwer

    Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • EtanerceptImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • Etravirinantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants : cyclosporine sirolimus tacrolimus ↓ immunosuppressant Etravirine and systemic immunosuppressants should be co-administered with caution because plasma concentrations of cyclosporine, sirolimus, or tacrolimus may be affected. (Fachinformation zu Etravirin, Arzneimittelwechselwirkungen)

  • EverolimusImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • FenofibratFibratMittelschwer

    Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (Fachinformation zu Fenofibrat, Arzneimittelwechselwirkungen)

  • FenofibrinsäureFibratMittelschwer

    Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (Fachinformation zu Fenofibrinsäure, Arzneimittelwechselwirkungen)

  • FingolimodImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • FondaparinuxAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Fosamprenavirantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: Cyclosporine, tacrolimus, sirolimus ↑ Immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents. (Fachinformation zu Fosamprenavir, Arzneimittelwechselwirkungen)

  • GuselkumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • HeparinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (Fachinformation zu Ketoconazol, Arzneimittelwechselwirkungen)

  • Ledipasvir und SofosbuvirVirostatikumMittelschwer

    HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Fachinformation zu Ledipasvir und Sofosbuvir, Warnhinweise und Vorsichtsmaßnahmen)

  • LeflunomidImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with KALETRA. (Fachinformation zu Lopinavir und Ritonavir, Arzneimittelwechselwirkungen)

  • MethotrexatImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • MycophenolatImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • NatalizumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • NefazodonAntidepressivumMittelschwer

    Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (Fachinformation zu Nefazodon, Arzneimittelwechselwirkungen)

  • Nevirapinantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: Cyclosporine, tacrolimus, sirolimus Plasma concentrations may be decreased. (Fachinformation zu Nevirapin, Arzneimittelwechselwirkungen)

  • OcrelizumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • Olmesartan, Amlodipin und HydrochlorothiazidAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Olmesartan, Amlodipin und Hydrochlorothiazid, Arzneimittelwechselwirkungen)

  • Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • PenicillaminMittelschwer

    Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (Fachinformation zu Penicillamin, Warnhinweise)

  • PentoxifyllinMethylxanthinMittelschwer

    Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • PimecrolimusCalcineurin-InhibitorMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • PonesimodImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • RifampicinAntibiotikumMittelschwer

    Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumMittelschwer

    …Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

  • RitlecitinibJAK-InhibitorMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • Ritonavirantiretrovirales ArzneimittelMittelschwer

    Immunosuppressants: cyclosporine, tacrolimus, sirolimus (rapamycin) ↑ immunosuppressants Therapeutic concentration monitoring is recommended for immunosuppressant agents when co-administered with ritonavir. (Fachinformation zu Ritonavir, Arzneimittelwechselwirkungen)

  • RituximabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • RivaroxabanAntikoagulans (Gerinnungshemmer)Mittelschwer

    Warfarin : Mercaptopurine tablets may decrease the anticoagulant effect. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • SecukinumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • SirolimusImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • Sofosbuvir und VelpatasvirVirostatikumMittelschwer

    HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (Fachinformation zu Sofosbuvir und Velpatasvir, Warnhinweise und Vorsichtsmaßnahmen)

  • Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • SulfasalazinSulfonamidMittelschwer

    Aminosalicylates Aminosalicylates (e.g., mesalamine, olsalazine or sulfasalazine) may inhibit the TPMT enzyme, which may increase the risk of myelosuppression when coadministered with mercaptopurine tablets. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • Telmisartan und AmlodipinAngiotensin-II-Rezeptorblocker (Sartan)Mittelschwer

    Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (Fachinformation zu Telmisartan und Amlodipin, Arzneimittelwechselwirkungen)

  • TemsirolimusMittelschwer

    Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (Fachinformation zu Temsirolimus, Warnhinweise und Vorsichtsmaßnahmen)

  • TeriflunomidImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • TheophyllinMethylxanthinMittelschwer

    Allopurinol Allopurinol can inhibit the first-pass oxidative metabolism of mercaptopurine by xanthine oxidase, which can lead to an increased risk of mercaptopurine adverse reactions (i.e., myelosuppression, nausea, and vomiting) [see Warnings and Precautions (5.1), Adverse Reactions (6.1)] . (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • TinidazolAntibiotikumMittelschwer

    Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (Fachinformation zu Tinidazol, Arzneimittelwechselwirkungen)

  • TocilizumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • TofacitinibImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • TrimethoprimAntibiotikumMittelschwer

    Enhanced myelosuppression has been noted in some patients also receiving trimethoprim-sulfamethoxazole. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

  • UpadacitinibImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • UstekinumabImmunsuppressivumMittelschwer

    A treatment regimen containing multiple immunosuppressants (including thiopurines) should therefore be used with caution as this could lead to lymphoproliferative disorders, some with reported fatalities. (Fachinformation zu Mercaptopurin, Warnhinweise und Vorsichtsmaßnahmen)

  • WarfarinAntikoagulans (Gerinnungshemmer)Mittelschwer

    Monitor the international normalized ratio (INR) in patients receiving warfarin and adjust the warfarin dosage as appropriate. (Fachinformation zu Mercaptopurin, Arzneimittelwechselwirkungen)

Geringfügige Erwähnungen (14)

  • AtorvastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Atorvastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • AxitinibGeringfügig

    Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (Fachinformation zu Axitinib, Warnhinweise und Vorsichtsmaßnahmen)

  • BusulfanGeringfügig

    During the pregnancy that resulted in the malformed infant, the mother received x-ray therapy early in the first trimester, mercaptopurine until the third month, then busulfan until delivery. (Fachinformation zu Busulfan, Warnhinweise)

  • Ezetimib und SimvastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Fachinformation zu Ezetimib und Simvastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • FluvastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (Fachinformation zu Fluvastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • LovastatinStatinGeringfügig

    IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Lovastatin, Warnhinweise)

  • NifedipinDihydropyridin-CalciumkanalblockerGeringfügig

    Immunosuppressive Drugs Tacrolimus: Tacrolimus has been shown to be metabolized via the CYP3A system. (Fachinformation zu Nifedipin, Vorsichtsmaßnahmen)

  • PitavastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Pitavastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • PosaconazolAzol-AntimykotikumGeringfügig

    CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (Fachinformation zu Posaconazol, Arzneimittelwechselwirkungen)

  • PravastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Pravastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • PropylthiouracilThyreostatikumGeringfügig

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Propylthiouracil, Warnhinweise)

  • RosuvastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (Fachinformation zu Rosuvastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • SimvastatinStatinGeringfügig

    IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (Fachinformation zu Simvastatin, Warnhinweise und Vorsichtsmaßnahmen)

  • ThiamazolThyreostatikumGeringfügig

    In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (Fachinformation zu Thiamazol, Warnhinweise)

Keine relevante Wechselwirkung berichtet (1)

  • ClarithromycinMakrolid-AntibiotikumKeine Wechselwirkung

    …Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (Fachinformation zu Clarithromycin, Arzneimittelwechselwirkungen)

Prüfen Sie Mercaptopurin gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.